The new and revolutionary HIV medication Atripla 600mg/200mg/300mg is now available for purchase.

Atripla is a once a day tablet for treating HIV-1 infection in adults.  It contains three antiretroviral drugs that have already been approved by the FDA. It combines the active ingredients of: Sustiva, Emtriva and Viread into one pill.  This is the first once a day single pill for HIV/AIDS.

Dr. Andrew C. von Eschenbach, Acting Commissioner of Food and Drugs, said "Today's approval is a significant example of drug developers and FDA clearing the way to quickly deliver quality, life-saving HIV/AIDS drugs to people who desperately need them in the United States and abroad. Fixed dose combination products are an important tool in improving the quality of health care in developing nations. The approval of Atripla is a significant step forward in our commitment to providing medical care as effectively and efficiently as possible. The approval of Atripla simplifies the treatment regimen for HIV-1 infected adults, and will potentially improve the ability of patients to adhere to treatment resulting in long-term effective control of HIV-1. This offers a particularly important advantage for patients in many countries that are most affected by the AIDS epidemic and will also have a major impact in the U.S. Atripla illustrates the outstanding achievements that are attainable when several pharmaceutical companies cooperate with our agency toward a common public health goal. I congratulate the three firms behind this unprecedented success -- and our reviewers, who worked with them every step of the way, on a job extremely well done."

Atripla can be purchased at CanadaDrugs.com for $1298.38/30 tablets by clicking on this link.